Department of Urology, Saarland University, Kirrbergerstrasse 1, Homburg/Saar, Germany.
World J Urol. 2012 Aug;30(4):495-503. doi: 10.1007/s00345-011-0796-7. Epub 2011 Nov 20.
Docetaxel had been the only treatment of castration-resistant prostate cancer (CRPC) that demonstrated a survival benefit for the patients. After its approval, no considerable progress has been made for several years until cabazitaxel and abiraterone acetate demonstrated a significant survival benefit in phase III clinical trials. Apart from that several other new drugs appeared including inhibitors of the androgen receptor (MDV3100), endothelin receptor antagonists (atrasentan, zibotentan), bone-targeted drugs (denosumab, Alpharadin) and immunotherapies (sipuleucel-T) capable of improving the prognosis of patients with CRPC. Here, we review the most recent advances in the treatment of CRPC and highlight the most promising new agents currently being investigated in clinical trials.
多西他赛是唯一一种在去势抵抗性前列腺癌（CRPC）患者中显示生存获益的治疗药物。在其获得批准后，数年时间内都没有取得显著进展，直到卡巴他赛和阿比特龙在 III 期临床试验中显示出显著的生存获益。除此之外，还有其他几种新药出现，包括雄激素受体抑制剂（MDV3100）、内皮素受体拮抗剂（阿曲生坦、齐帕特罗）、骨靶向药物（地舒单抗、阿仑膦酸钠）和免疫疗法（sipuleucel-T），这些药物都有可能改善 CRPC 患者的预后。在这里，我们回顾了 CRPC 治疗的最新进展，并强调了目前正在临床试验中研究的最有前途的新药。
